Samsung Drug-making Unit Soars On Market Debut
Mohammad Ali (@ChaudhryMAli88) Published November 10, 2016 | 01:20 PM
SEOUL, , (APP - UrduPoint / Pakistan Point News - 10th Nov, 2016 ) - Shares in Samsung's drug-making unit soared almost six percent on their market debut Thursday, after one of South Korea's biggest ever initial public offerings that raised nearly $2 billion.
samsung Biologics, a contract manufacturer of biotech drugs for global pharmaceutical firms, surged 5.88 percent from its IPO price to close at 144,000 won ($125) in Seoul, putting its total value at about 9.5 trillion won.
The rally came as investors snapped up pharmaceutical shares after Donald Trump victory in the US presidential election, during which rival Hillary Clinton had said she would move to lower drugs prices.
The pharma sector rallied eight percent in Seoul. Samsung Biologics was set up by the South Korean conglomerate in 2011 as part of a multi-billion-dollar drive to find new growth avenues including healthcare and green energy over the next decade.
The highly anticipated IPO is the second largest in South Korea's history, raising 2.25 trillion won ($1.96 billion), which the unit says will be used to expand production capacity and invest in research and development.
The firm makes biopharmaceutical drugs for major firms including Bristol-Myers Squibb and Roche at plants near Seoul. Bio-drugs, unlike chemically synthesised drugs, are made of organic, live substances such as plant or animal cells and are more complex to research and manufacture.
Construction unit Samsung C&T and the flagship Samsung Electronics together hold a 75 percent stake in Samsung Biologics after the share sale. The firm has been in the red for years with a net loss of 75.7 billion won in 2015 as it invested heavily in its two existing plants and a new facility slated to open in two years.
Completion of the third plant is expected to make the company the world's top contract drug manufacturer in terms of production capacity, said Woo Chang-Hee, analyst at IBK Investment & Securities. The global biopharmaceutical market is expected to grow to $488 billion by 2025, compared with $164 billion in 2012, due to the world's ageing population, Woo said.
Related Topics
Recent Stories
Mahira Khan delights at Arijit Singh’s concert in Dubai
Dubai Customs Celebrates World Intellectual Property Day, Honors Schools and Uni ..
Vivo Reveals Durefishan Saleem as Brand Ambassador for its Upcoming Y100 Smartph ..
FIA investigates alleged irregularities in tickets’ sale for PSL, int’l matc ..
IMF approves $1.1b final tranche for Pakistan
Naseem Shah among others who registers for LPL 2024
NAB withdraws LNG reference against Shahid Khaqan Abbasi
Mohsin Naqvi to visit Karachi today
Currency Rate In Pakistan - Dollar, Euro, Pound, Riyal Rates On 30 April 2024
Today Gold Rate in Pakistan 30 April 2024
Wembanyama in France: NBA Spurs to play Pacers in Paris in January
Russian missile kills two in Ukraine's Odesa: governor
More Stories From World
-
Sword-wielding man held in east London after attacks
5 minutes ago -
Indonesia volcano erupts, thousands evacuated over tsunami threat
25 minutes ago -
Ecuador embassy raid crossed line, top UN court told
45 minutes ago -
Dubai Customs Celebrates World Intellectual Property Day, Honors Schools and Universities Award Winn ..
53 minutes ago -
ChatGPT faces Austria complaint over 'uncorrectable errors'
1 hour ago -
Indian forest activist at the coalface of mining battle
1 hour ago
-
China says Palestinian groups met for talks in Beijing
1 hour ago -
Columbia suspends students after call to end Gaza camp unheeded
1 hour ago -
Ex-Binance chief set for sentencing in US court
1 hour ago -
Chinese scientists develop fast breeding rice in Xinjiang desert greenhouses
1 hour ago -
Minister of communications discusses strengthening partnership to expand growth of digital economy, ..
1 hour ago -
Vardy leads Leicester to Championship title
2 hours ago